Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population
Open Access
- 16 October 2022
- journal article
- research article
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 21 (1) , 1-14
Abstract
Background: Peripheral arterial disease (PAD) is one of the most disabling cardiovascular complications of type 2 diabetes mellitus and is indeed associated with a high risk of cardiovascular and limb adverse events. High mobility group box-1 (HMGB-1) is a nuclear protein involved in the inflammatory response that acts as a pro-inflammatory cytokine when released into the extracellular space. HMBG-1 is associated with PAD in diabetic patients. The aim of this study was to evaluate the association between serum HMGB-1 levels and major adverse cardiovascular events (MACE) and major adverse limb events (MALE) after lower-extremity endovascular revascularization (LER) in a group of diabetic patients with chronic limb-threatening ischemia (CLTI). Methods: We conducted a prospective observational study of 201 diabetic patients with PAD and CLTI requiring LER. Baseline serum HMGB-1 levels were determined before endovascular procedure. Data on cardiovascular and limb outcomes were collected in a 12-month follow-up. Results: During the follow-up period, 81 cases of MACE and 93 cases of MALE occurred. Patients who subsequently developed MACE and MALE had higher serum HMGB-1 levels. Specifically, 7.5 ng/mL vs 4.9 ng/mL (p < 0.01) for MACE and 7.2 ng/mL vs 4.8 ng/mL (p < 0.01) for MALE. After adjusting for traditional cardiovascular risk factors, the association between serum HMGB-1 levels and cardiovascular outcomes remained significant in multivariable analysis. In our receiver operating characteristic (ROC) curve analysis, serum HMGB-1 levels were a good predictor of MACE incidence (area under the curve [AUC] = 0.78) and MALE incidence (AUC = 0.75). Conclusions: This study demonstrates that serum HMGB-1 levels are associated with the incidence of MACE and MALE after LER in diabetic populations with PAD and CLTI.Keywords
All Related Versions
This publication has 66 references indexed in Scilit:
- HMGB1 Is Associated with Atherosclerotic Plaque Composition and Burden in Patients with Stable Coronary Artery DiseasePLOS ONE, 2012
- Plasma High-Mobility Group Box 1 Levels Predict Mortality After ST-Segment Elevation Myocardial InfarctionJACC: Cardiovascular Interventions, 2011
- High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent MechanismDiabetes, 2010
- Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patientsAtherosclerosis, 2009
- High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-κB and Egr-1Thrombosis and Haemostasis, 2009
- Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodellingCardiovascular Research, 2008
- High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the HeartCirculation, 2008
- Pro‐inflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemiaJournal of Internal Medicine, 2007
- Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 proteinThe FASEB Journal, 2006
- High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenalNature Reviews Immunology, 2005